Vasodilators Global Market Report 2024

Vasodilators are medicines that expand blood vessels by relaxing the smooth muscle cells in vessel walls, particularly in large arteries and veins. They are prescribed to manage conditions such as hypertension (high blood pressure), angina (chest pain), and heart failure, aiming to lessen the heart's workload and enhance circulation.

The primary types of vasodilators include arterial dilators, venous dilators, and mixed dilators. Arterial dilators primarily widen arteries, improving blood flow from the heart throughout the body. Examples of these medications are nitroglycerin, alprostadil, minoxidil, and sorbitrate. They are administered via oral, parenteral, and other routes, and are utilized across various settings including hospitals, homecare, specialty centers, among others.

The vasodilators market research report is one of a series of new reports that provides vasodilators market statistics, including vasodilators industry global market size, regional shares, competitors with a vasodilators market share, detailed vasodilators market segments, market trends and opportunities, and any further data you may need to thrive in the vasodilators industry. This vasodilators market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The vasodilators market size has grown strongly in recent years. It will grow from $6.01 billion in 2023 to $6.4 billion in 2024 at a compound annual growth rate (CAGR) of 6.4%. The growth observed in the historic period can be attributed to heightened awareness and improved diagnosis, governmental initiatives and healthcare policies, increasing health consciousness among populations, advancements in gene therapy, and the expanding adoption of artificial intelligence.

The vasodilators market size is expected to see strong growth in the next few years. It will grow to $8.22 billion in 2028 at a compound annual growth rate (CAGR) of 6.5%. The growth in the forecast period can be linked to the escalating prevalence of hypertension and cardiovascular diseases, rising demand for advanced medical technologies addressing cardiac ailments, a globally increasing geriatric demographic, growing incidences of diabetes and high blood pressure, and the growing significance of personalized medicine. Key trends expected in the forecast period encompass strategic mergers and acquisitions, a shift towards outpatient and home-based care settings, innovations in product offerings, technological advancements, and the expansion of healthcare infrastructure.

The vasodilators market is poised for growth due to the increasing incidence of cardiovascular diseases. These diseases, which include coronary artery disease, heart failure, and stroke, are often associated with hypertension and other risk factors, fueled by sedentary lifestyles, unhealthy diets, obesity, tobacco use, and aging populations. Vasodilators play a crucial role in managing cardiovascular conditions by relaxing blood vessels, lowering blood pressure, and enhancing blood flow. In May 2024, the Centers for Disease Control and Prevention reported that coronary artery disease alone caused 375,476 deaths in 2021, affecting approximately 1 in 20 adults aged 20 and above. Hence, the upward trend in cardiovascular diseases is a key driver of the vasodilators market's expansion.

The increasing prevalence of sedentary lifestyles is expected to drive growth in the vasodilators market. Sedentary lifestyles, characterized by limited physical activity and prolonged periods of sitting or lying down, are becoming more common due to modern conveniences such as technology and desk-bound jobs. This trend is fueled by technological advancements and work environments that prioritize convenience over movement. Vasodilators play a crucial role in mitigating cardiovascular risks associated with sedentary lifestyles by improving blood flow and reducing hypertension. For example, data from the Centers for Disease Control and Prevention in September 2023 showed that 22 states in the US had an adult obesity rate of 35% or higher, up from 19 states in 2021, highlighting the growing impact of sedentary lifestyles. This trend is a key driver for the vasodilators market's growth.

Major players in the vasodilators market are concentrating on developing advanced products such as soluble guanylate cyclase (sGC) stimulators to gain a competitive advantage. Soluble guanylate cyclase (sGC) is an enzyme primarily found in cells, particularly in the smooth muscle cells lining blood vessels. Activation of sGC converts guanosine triphosphate (GTP) into cyclic guanosine monophosphate (cGMP), leading to vasodilation and increased blood flow. For instance, in September 2022, Bayer AG, a pharmaceutical and biotechnology company based in Germany, introduced Vericiguat (Verquvo), an sGC stimulator designed for adults with symptomatic chronic heart failure. This drug targets a pathway not addressed by current treatments, thus reducing the risk of cardiovascular death and hospitalization. This strategic focus on innovative products such as sGC stimulators reflects the industry's drive to offer more effective solutions for cardiovascular conditions.

Major companies operating in the vasodilators market are Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, Abbott Laboratories, GlaxoSmithKline Plc., Eli Lilly and Company, Gilead Sciences Inc., Amgen Inc., AstraZeneca, Mayo Foundation for Medical Education and Research (MFMER), Boehringer Ingelheim International GmbH, Bayer AG, Viatris Inc., Novo Nordisk A/S, Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Biogen.

North America was the largest region in the vasodilators market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the vasodilators market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the vasodilators market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The vasodilators market consists of sales of tablets, capsules, injectable solutions, transdermal patches, oral solutions, sublingual tablets, intravenous infusions, topical creams, and gels. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.